MYNZ
Mainz Biomed B.V.
Set alert
3.59 USD 0.00 0.00%
3.38 Day range 3.72
0.18 52-week range 7.95
- YTD
- +220.54%
- 1 year
- +41.34%
- Open
- 3.65
- Prev close
- 3.59
- Mkt cap
- 11.02M
- Vol
- 6.00M
- Avg vol
- 3.08M
- EPS
- -44.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.38
- High
- 3.72
- Forward P/E
- -6.70
- Beta
- 0.08
- Short ratio
- 0.63
- Inst. own
- 0.22%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 26, 2024
- 50-d avg
- 1.81
- 200-d avg
- 0.889895
- 1y target
- 0.00
Key statistics
- Market cap
- 11.02M
- Enterprise value
- 178.21M
- Trailing P/E
- 0.00
- Forward P/E
- -6.70
- PEG ratio
- 0.00
- Price / sales
- 12.01
- Price / book
- 0.00
- EPS (TTM)
- -44.40
- Beta
- 0.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 917.20K
- Revenue growth
- 4.60%
- Free cash flow
- -12.58M
- Total cash
- 977.76K
- Total debt
- 8.27M
- Return on equity
- -4333.71%
- Shares outstanding
- 2.22M
- Short % of float
- 4.59%
- 50-day average
- 1.81
- 200-day average
- 0.889895
Analyst view
Consensus: none
Price target (mean) 0.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Dec 26, 2024
Expected Dec 26, 2024. Consensus EPS estimate 0.00.
Financials — quick view
MYNZ Revenue — quarterly 214.76K
MYNZ Net income — quarterly -5.18M
MYNZ EPS — quarterly -9.76
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 26, 2024 | Sep 1, 2024 | -4.40 | — | — | — |
| Oct 1, 2024 | Jun 1, 2024 | -0.25 | — | — | — |
| Jul 2, 2024 | Mar 1, 2024 | -0.31 | — | — | — |
| Apr 9, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Apr 9, 2024 | Dec 1, 2023 | 0.00 | -9.60 | — | — |
| Nov 16, 2023 | Sep 1, 2023 | -20.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 12, 2024 | Cantor Fitzgerald | reit | — | Neutral |
| Mar 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 21, 2023 | Cantor Fitzgerald | down | Overweight | Neutral |
| Nov 20, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 26, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Mainz Biomed B.V.
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- Germany
- Website
- mainzbiomed.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MYNZ — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vontobel Holding Limited | 0.06% | 1,125 | 5.58K | Sep 29, 2024 |
| Northern Trust Corporation | 0.04% | 748 | 3.71K | Sep 29, 2024 |
| Steward Partners Investment Advisory, LLC | 0.04% | 725 | 3.60K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.03% | 588 | 2.92K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.02% | 380 | 1.88K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.02% | 364 | 1.80K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 225 | 1.12K | Oct 30, 2024 |